¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"antibody induced lysis"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • steroid-induced atrophy
    ½ºÅ×·ÎÀ̵åÀ¯¹ßÀ§Ãà
  • steroid-induced glaucoma
    ½ºÅ×·ÎÀ̵å³ì³»Àå
  • antibody
    Ç×ü
  • antibody absorption
    Ç×üÈí¼ö
  • antibody capture enzyme-linked immunosorbent assay
    Ç×üÆ÷ȹȿ¼Ò¸é¿ªÃøÁ¤(¹ý)
  • antibody diversity
    Ç×ü´Ù¾ç¼º
  • antibody excess
    Ç×ü°úÀ×
  • antibody excess zone
    Ç×ü°úÀ×±¸¿ª
  • antibody half-life
    Ç×ü¹Ý°¨±â
  • antibody identification test
    Ç×üȮÀΰ˻ç
  • antibody removal
    Ç×üÁ¦°Å
  • antibody screening test
    Ç×ü¼±º°°Ë»ç
  • antibody synthesis
    Ç×üÇÕ¼º
  • antibody valence
    Ç×ü°áÇÕ°¡
  • antibody-binding site
    Ç×ü°áÇÕºÎÀ§
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • radiation-induced myelopathy
    ¹æ»ç¼±À¯¹ßô¼öº´Áõ
  • pregnancy induced retinopathy
    ÀÓ½ÅÀ¯¹ß¸Á¸·º´Áõ
  • radiation-induced
    ¹æ»ç¼±À¯¹ß-
  • virus-induced tumor
    ¹ÙÀÌ·¯½ºÀ¯¹ßÁ¾¾ç
  • antibody
    Ç×ü
  • anaphylactic antibody
    ¾Æ³ªÇʶô½Ã½ºÇ×ü
  • anti-idiotype antibody
    Ç×À̵ð¿ÀŸÀÔÇ×ü, Ç×°³º°Æ¯ÀÌÇüÇ×ü
  • antibody diversity
    Ç×ü´Ù¾ç¼º
  • antibody excess
    Ç×ü°úÀ×
  • antibody half-life
    Ç×ü¹Ý°¨±â
  • antibody removal
    Ç×üÁ¦°Å
  • antibody synthesis
    Ç×üÇÕ¼º
  • antibody titer
    Ç×ü°¡
  • antibody transfer
    Ç×üÀÌÀÔ
  • antibody valence
    Ç×ü°áÇÕ°¡
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • Donath-Landsteiner antibody
    µµ³ª¾²¶õÆ®½ºÅ¸ÀÌ³Ê Ç×ü
  • FTA (fluorescent treponemal antibody)
    ¸Åµ¶Çü±¤Ç×ü °Ë»ç¹ý
  • Fy antigen/antibody
    Fy Ç׿ø/Ç×ü
  • Gp 120/160 antibody
    Gp 120/160 Ç×ü
  • Gp 24 antibody
    Gp 24 Ç×ü
  • I antibody
    I Ç×ü
  • Jk antigen/antibody
    JkÇ׿ø/Ç×ü
  • Jo-1 antibody
    Jo-1 Ç×ü
  • Kell antigen and antibody
    ÄÌÇ׿øÇ×ü
  • Langmuir expression in drug-antibody binding
    ¾à¹°-Ç×ü °áÇÕ¿¡¼­ÀÇ ¶û¹¿¸£Ç¥Çö
  • Lewis antibody
    ·çÀ̽ºÇ×ü
  • Lutheran antibody
    ·çÅ×¶õÇ×ü
  • M2 antibody
    M2 Çü Ç×ü
  • P antibody
    P Ç×ü
  • Scl-70 antibody
    Scl-70 Ç×ü
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • drug-induced nystagmus
    ¾à¹°¾ÈÁø
  • drug-induced psychosis
    ¾à¹°À¯¹ß Á¤½ÅÁõ
  • drug-induced purpura
    ¾à¹° À¯¹ß ÀÚ¹Ý(º´)(í¹Úè
  • drug-induced rhinitis =rhinitis medicamentosa <³ª
    ¾à¹°(¼º) ºñ¿°
  • drug-induced systemic lupus erythematosus
    ¾à¹°À¯¹ß Àü½Å¼ºÈ«¹Ý¼º ·çǪ½º
  • drug-induced vasculitis
    ¾à¹° À¯¹ß Ç÷°ü¿°
  • exercise-induced anaphylaxis
    ¿îµ¿ À¯µµ¼º À̳ªÇʶô½Ã½º
  • exercise-induced hematuria
    ¿îµ¿À¯¹ßÇ÷´¢
  • fat induced hyperlipemia
    ÁöÁúÀ¯µµ¼º °íÁö¹æÇ÷Áõ.
  • gradient induced phase shift effect
    °æ»ç À¯µµ À§»ó º¯À§ È¿°ú
  • hallucinogen-induced disorder
    ȯ°¢Á¦ À¯¹ß¼ºÀå¾Ö(º´)(ü³ÊÆð¥ë¯Û¡àõî¡äô)
  • hearing loss, noise induced
    ¼ÒÀ½¼º³­Ã»
  • heat induced hemolytic anemia
    ¿­À¯¹ß¼º ¿ëÇ÷¼º ºóÇ÷
  • induced abortion =provoked a.
    À¯¹ßÀ¯»ê(ë¯Û¡êüß§), ÀΰøÀ¯»ê(ìÑÍïêüß§) .
  • induced allergy
    À¯¹ß(¼º)¾Ë·¹¸£±â
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
  • cold antibody
    ³ÃÇ×ü(Ò²ù÷ô÷)
  • complement-fixing antibody
    º¸Ã¼°íÁ¤ Ç×ü(ÜÍô÷ͳïÒù÷ô÷)
  • complete antibody
    ¿ÏÀüÇ×ü(èÇîïù÷ô÷)
  • coprecipitating antibody
    °øÄ§Àü(ÍìöØîþ) Ç×ü(ù÷ô÷)
  • cross-reacting antibody
    ±³Â÷¹ÝÀÀ Ç×ü(Îßó©Úãëëù÷ô÷)
  • cytophilic antibody
    ¼¼Æ÷ģȭÇ×ü(á¬øàöÑûúù÷ô÷)
  • cytotoxic antibody
    ¼¼Æ÷µ¶¼º Ç×ü(á¬øàÔ¸àõù÷ô÷)
  • cytotropic antibody
    ¼¼Æ÷ģȭ¼º Ç×ü(á¬øàöÑûúàõù÷ô÷)
  • direct fluorescent antibody technique
    Á÷Á¢ Çü±¤ Ç×ü¼ú(òÁïÈû«ÎÃù÷ô÷âú)
  • ferritin-labeled antibody
    Æä¸®Æ¾Ç¥Áö(øöò½) Ç×ü(ù÷ô÷)
  • fluorescent antibody
    Çü±¤ Ç×ü(û«ÎÃù÷ô÷)
  • fluorescent antibody technique
    Çü±¤ Ç×ü¼ú(û«ÎÃù÷ô÷âú)
  • fraction-antibody binding
    ºÎºÐÇ×ü °áÇÕ(Ý»ÝÂù÷ô÷Ì¿ùê)
  • hemolytic antibody
    ¿ëÇ÷ Ç×ü(éÁúìù÷ô÷)
  • heterocytotropic antibody
    ÀÌÁ¾Ä£È­¼º Ç×ü(ì¶ðúöÑûúàõù÷ô÷)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
ECLT euglobulin clot lysis time
EGLT euglobin lysis time
ELT endless loop tachycardia; euglobulin lysis time
HLB hydrophilic-lipophilic balance; hypotonic lysis buffer
ImLy immune lysis
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 4
AIA Antigen induced arthritis
AIA Aspirin induced Asthma
CIA C II)-induced arthritis
CICR Ca induced Ca release
CICR Ca(+2)-induced Ca+2 release
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antibody excess zone
    Ç×ü °úÀ׿ª
  • antibody half-life
    Ç×ü ¹Ý°¨±â
    Ç×ü ºÐÀÚ°¡ Çü¼ºµÈ ÈÄ Æò±Õ »ýÁ¸ÇÏ´Â ½Ã°£À» ÃøÁ¤ÇÏ´Â °ÍÀ¸·Î¼­, º¸Åë µ¿¹°Ã¼³»¿¡¼­ ÀÏÁ¤·®ÀÇ ¸é¿ª ±Û·ÎºÒ¸°ÀÇ 50%¸¦ Á¦°ÅÇÏ´Â µ¥ °É¸®´Â ½Ã°£À¸·Î Ç¥½ÃÇÑ´Ù. ÀÌ ¹Ý°¨±â´Â ¸é¿ª ±Û·ÎºÒ¸°ÀÇ Á¾·ù¿¡ µû¶ó ´Ù¸£´Ù.
  • antibody response
    Ç×ü ¹ÝÀÀ
  • antibody synthesis
    Ç×ü »ý»ê, Ç×ü ÇÕ¼º
    µ¿ÀǾî=antibody
  • antibody titer
    Ç×ü ¿ª°¡
  • antibody-drug-cell complex
    Ç×ü ¾à¹° ¼¼Æ÷ º¹ÇÕü
  • antigen antibody complex
    Ç׿ø Ç×ü º¹ÇÕü
    Ç׿ø°ú Ç×ü°¡ °áÇÕÇÑ °Í. ¸é¿ª º¹ÇÕü¶ó°íµµ ÇÑ´Ù. Ç×ü´Â Ç׿ø°ú °áÇÕÇÏ¿© º¹ÇÕü¸¦ ¸¸µé¸é º¸Ã¼ Ȱ¼ºÈ­ ÀÛ¿ëÀ» °¡Áö°Ô µÈ´Ù. ±×·¡¼­ »ýü ³»¿¡¼­ ¸é¿ª º¹ÇÕü°¡ Çü¼ºµÇ¸é ±× ÁÖº¯¿¡¼­ ºÎü°¡ Ȱ¼ºÈ­µÇ¾î ¿°Áõ¹ÝÀÀÀ» ¹ß»ý½ÃŰ´Â ¼ÀÀÌ´Ù. Ç׿ø Ç×ü º¹ÇÕü´Â ħ°­¼ºÀÇ °ÍÀ¸·Î µÇ±â ½±´Ù. µû¶ó¼­ Ç׿øÀÇ Ä§ÀÔ ºÎÀ§¿¡ ¿°Áõ¹ÝÀÀÀÌ »ý±â±â ½±´Ù.
  • antigen antibody reaction
    Ç׿ø Ç×ü ¹ÝÀÀ
  • antigen-antibody reaction
    Ç׿ø-Ç×ü ¹ÝÀÀ
  • antiglobulin antibody
    Çױ۷κθ° Ç×ü
  • antiinsulin antibody
    Ç×Àν¶¸° Ç×ü
  • antinuclear antibody
    Ç×ÇÙ Ç×ü
    ÇÙ Ç׿ø¿¡ ´ëÇÑ Ç×ü·Î¼­ º¸Åë Àü½Å¼º È«¹Ý¼º ³¶Ã¢À» °¡Áø ȯÀÚÀÇ Ç÷û¿¡¼­ ¹ß°ßµÈ´Ù. ±×·¯³ª ·ù¸¶Æ¼¼º °üÀý¿°, °øÇÇÁõ ±×¸®°í ´Ù¸¥ °áÇÕÁ¶Á÷Àå¾Ö ȯÀÚ¿¡¼­µµ ¹ß°ßµÈ´Ù.
  • antiphospholipid antibody
    Ç×ÀÎÁöÁú Ç×ü
  • antiplatelet antibody
    Ç×Ç÷¼ÒÆÇ Ç×ü
  • blocking antibody
    Â÷´Ü Ç×ü
    µ¿ÀǾî=blocker.
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 4
induced mutation A mutation caused by exposure to a mutagen.
(05 Mar 2000)
induced phagocytosis <cell biology> Phagocytosis occurring when bacteria subjected to the action of blood serum are brought in contact with leukocytes.
(05 Mar 2000)
induced psychotic disorder <psychiatry> A severe mental disorder brought about by a toxic agent such as a drug or hallucinogen.
See: psychosis.
(05 Mar 2000)
induced radioactivity artificial radioactivity
induced sensitivity 1. <immunology> A state of hypersensitivity induced by exposure to a particular antigen (allergen) resulting in harmful immunologic reactions on subsequent exposures, the term is usually used to refer to hypersensitivity to an environmental antigen (atopic allergy or contact dermatitis) or to drug allergy.
The original meaning, now obsolete, included all states of altered immunologic reactivity, immunity as well as hypersensitivity. Gell and Coombs used the term allergic reaction to mean any harmful immunologic reaction causing tissue injury.
2. <study> The medical specialty dealing with diagnosis and treatment of allergic disorders.
(18 Nov 1997)
induced symptom A symptom excited by a drug, exercise, or other means, often intentionally for diagnostic purposes.
(05 Mar 2000)
induced trance The artificially induced state of hypnosis or of somnambulistic trance.
(05 Mar 2000)
iodine-induced hyperthyroidism <endocrinology> Induction of thyrotoxicosis in a previously euthyroid individual as a result of exposure to large quantities of iodine.
It occurs most often in areas of endemic iodine-deficient goiter and in patients with multinodular goiter. It can also can develop following use of iodine-containing agents for diagnostic studies.
Synonym: iodine-induced hyperthyroidism.
(05 Mar 2000)
effort-induced thrombosis <syndrome> Stress thrombosis or spontaneous thrombosis of the subclavian or axillary vein; a thoracic-outlet syndrome.
Synonym: effort-induced thrombosis.
(05 Mar 2000)
exercise-induced amenorrhoea The temporary cessation of menstrual function due to strenuous, daily exercise, as in jogging; increased endorphins inhibiting hypothalamic function.
(05 Mar 2000)
familial fat-induced hyperlipaemia Hyperlipoproteinaemia characterised by the presence of large amounts of chylomicrons and triglycerides in the plasma when the patient has a normal diet, and their disappearance on a fat-free diet; low alpha-and beta-lipoproteins on a normal diet, with increase on fat-free diet; decreased plasma postheparin lipolytic activity; and low tissue lipoprotein lipase activity. It is accompanied by bouts of abdominal pain, hepatosplenomegaly, pancreatitis, and eruptive xanthomas; autosomal recessive inheritance.
See: familial lipoprotein lipase inhibitor.
Synonym: Burger-Grutz syndrome, familial fat-induced hyperlipaemia, familial hyperchylomicronaemia, familial hypertriglyceridemia, idiopathic hyperlipaemia.
(05 Mar 2000)
lens-induced uveitis Intraocular inflammation occurring after extracapsular cataract extraction;probably an immune reaction to the patient's liberated lenticular proteins.
Synonym: lens-induced uveitis.
(05 Mar 2000)
leucine-induced hypoglycaemia Rare cause of hypoglycaemia occurring following ingestion of leucine. Seen especially in infants.
(05 Mar 2000)
ligand induced endocytosis The formation of coated pits and then coated vesicles as a consequence of the interaction of ligand with receptors, which then interact with clathrin and associated proteins (coatomers) on the cytoplasmic face of the plasma membrane and come together to form a pit. Not all coated vesicle uptake of receptors requires receptor occupancy.
(18 Nov 1997)
affinity antibody The measure of the interaction between molecules such as a receptor and its ligand. This interaction is reversible.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 4
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 4
ÅëÇÕ°Ë»ö ¿Ï·á